ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

(2011) Timothy R. Wilson et al.   CANCER CELL

A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody

(2011) H. Glantschnig et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis

(2011) T Smirnova et al.   ONCOGENE

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation

(2010) A. Jain et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Spatial control of EGF receptor activation by reversible dimerization on living cells

(2010) Inhee Chung et al.   NATURE

Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review

(2010) L. S. Rosen et al.   ONCOLOGIST

Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver

(2010) D. N. Amin et al.   Science Translational Medicine

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

(2009) Katrine Sonne-Hansen et al.   BREAST CANCER RESEARCH AND TREATMENT

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells

(2009) M. Narayan et al.   CANCER RESEARCH

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

(2009) E. A. Mittendorf et al.   CLINICAL CANCER RESEARCH

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

(2009) Y. Nagumo et al.   MOLECULAR CANCER RESEARCH

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

(2009) Y.-K. Yoon et al.   MOLECULAR CANCER THERAPEUTICS

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens

(2009) Alice C Fan et al.   NATURE MEDICINE

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis

(2009) B. Schoeberl et al.   Science Signaling

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

HER3 Is a Determinant for Poor Prognosis in Melanoma

(2008) M. Reschke et al.   CLINICAL CANCER RESEARCH

Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes

(2008) Z Cai et al.   ONCOGENE